Hims & Hers Agrees To Buy Eucalyptus In $1.15 Bil Deal. Stock Rallies.

CoffeeNFTs · 2026-02-20T15:49:13+00:00

Hims & Hers is acquiring Eucalyptus for $1.15 billion to enhance its international reach, particularly in Australia, Japan, and Europe. The deal includes a $240 million cash payment and aims to transform personalized healthcare while navigating current challenges.

CoffeeNFTs

2026-02-20 15:49:13

Abstract generation in progress

Hims & Hers has agreed to buy digital health firm Eucalyptus in a $1.15 billion deal aimed at expanding into new international markets.

Hims (HIMS) stock rallied nearly 4% in early trades.

				    ↑
					X

This video file cannot be played.(Error Code: 102630)

								Stocks Bounce, Hit Resistance; ASML, BrightSpring Health, Ralph Lauren In Focus
							

							

								See All Videos
							

						

					
					
						NOW PLAYING
						Stocks Bounce, Hit Resistance; ASML, BrightSpring Health, Ralph Lauren In Focus

Hims & Hers will pay roughly $240 million in cash upon the closing of the deal, the company said.

“Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada,” the company added.

In a statement, Hims & Hers Chief Executive Andrew Dudum said, “With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform health care into a customer-first, personalized industry.”

Hims & Hers unveiled the acquisition as the company grappled with new challenges. Novo Nordisk has sued the company which is known for making a knockoff version of Novo’s oral weight loss drug Wegovy. The Food and Drug Administration also said it plans to look into the marketing of copycat drugs.

YOU MAY ALSO LIKE:

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk

Amazon Stock Is Slumping. But The Tech Giant Just Dethroned Walmart For This Milestone.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.